Video
Dr. Locke Discusses Long-Term Follow-Up of ZUMA-1 Trial for NHL
Author(s):
Frederick Locke, MD, a medical oncologist in the Department of Blood and Marrow Transplant at Moffitt Cancer Center, and an assistant professor of Oncology at the University of South Florida, discusses long-term follow-up results of the ZUMA-1 trial for patients with non-Hodgkin lymphoma (NHL).
Frederick Locke, MD, a medical oncologist in the Department of Blood and Marrow Transplant at Moffitt Cancer Center, and an assistant professor of Oncology at the University of South Florida, discusses long-term follow-up results of the ZUMA-1 trial for patients with non-Hodgkin lymphoma (NHL).
The FDA has approved the CD19-directed chimeric antigen receptor (CAR) T-cell therapy axicabtagene ciloleucel (axi-cel; Yescarta) as a treatment for adults with relapsed or refractory NHL, based on complete remission (CR) rates in the phase II ZUMA-1 trial.
In the single-arm ZUMA-1 study, axi-cel demonstrated an objective response rate (ORR) of 82% and a CR rate of 54%. After 8.7 months of follow-up, 39% of patients remained in CR. The median duration of response in those with a CR was not reached at the time of assessment (95% CI, 8.1-not estimable). The label for the medication lists the ORR as 72% and the CR rate as 51% (95% CI, 41%-62%).
